AMAG Pharmaceuticals (NASDAQ:AMAG) : 4 brokerage houses believe that AMAG Pharmaceuticals (NASDAQ:AMAG) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on AMAG Pharmaceuticals (NASDAQ:AMAG). Zacks Investment Research suggests a Strong Sell with a rank of 5.The median of all the 8 Wall Street Analysts endorse the stock as a Buy with a rating of 2.
AMAG Pharmaceuticals (NASDAQ:AMAG) : 7 investment research analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG) have an average price target of $46.29 for the near short term. The highest target price given by the Brokerage Firm to the stock is $80 and the lowest target is $27 for the short term. Analysts expect the variance to be within $18.15 of the average price.
For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Raymond James downgrades its ratings on AMAG Pharmaceuticals (NASDAQ:AMAG). According to the latest information available, the shares are now rated Market Perform by the analysts at the agency. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 4, 2016.
AMAG Pharmaceuticals (NASDAQ:AMAG): stock turned positive on Tuesday. Though the stock opened at $22.47, the bulls momentum made the stock top out at $23.19 level for the day. The stock recorded a low of $22.41 and closed the trading day at $23.15, in the green by 4.99%. The total traded volume for the day was 938,214. The stock had closed at $22.05 in the previous days trading.
In an insider trading activity, Fallon John A., director of Amag Pharmaceuticals Inc., executed a transaction worth $100,776 on November 10, 2015. A total of 3,230 shares were purchased at an average price of $31.2. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.